BIO-Europe: 30 years of facilitating partnerships
November 4–6, 2024 I Stockholm, Sweden,
Experience BIO-Europe and connect with delegates spanning the global life science ecosystem to propel dealmaking and innovation. BIO-Europe will feature a distinguished lineup of speakers, including leading experts and visionaries from the biotech and pharma industries, who will take you on a journey of the past 30 years of experiences, partnerships and innovation and envision trends in the next 30 years to come.
About EnnoDC
EnnoDC is a clinical-stage biotech company pioneering the development of first-in-class dendritic cell-targeting IgG4 CD40 and antigen-specific immunotherapies for cancer and infectious diseases.
We have a growing pipeline of novel therapeutic antibodies, several of which are in clinical development. Target cancers include HPV16+ oropharyngeal and prostate cancer, and infectious diseases, HIV and COVID.
Our groundbreaking and versatile technology platform harnesses the power of immunotherapy and vaccines by stimulating dendritic cells (DCs) to deliver a more targeted and effective immune response compared to current treatments.
Contact
Christophe Hubert, CEO
contact@ennodc.com
